A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam ; volume:24 ; number:1 ; day:5 ; month:2 ; year:2024 ; pages:1-10 ; date:12.2024
BMC cancer ; 24, Heft 1 (5.2.2024), 1-10, 12.2024
- Urheber
-
Pham, Cam Phuong
Nguyen, Thi Thai Hoa
Do, Anh Tu
Nguyen, Tuan Khoi
Hoang, Thi Anh Thu
Le, Tuan Anh
Vuong, Dinh Thy Hao
Nguyen, Dac Nhan Tam
Dang, Van Khiem
Nguyen, Thi Oanh
Pham, Van Luan
Nguyen, Minh Hai
Vo, Thi Huyen Trang
Do, Hung Kien
Vu, Ha Thanh
Nguyen, Thi Thuy Hang
Pham, Van Thai
Trinh, Le Huy
Nguyen, Khac Dung
Nguyen, Hoang Gia
Truong, Cong Minh
Pham, Tran Minh Chau
Nguyen, Thi Bich Phuong
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-024-11891-w
- URN
-
urn:nbn:de:101:1-2024041510170527832405
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:49 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Pham, Cam Phuong
- Nguyen, Thi Thai Hoa
- Do, Anh Tu
- Nguyen, Tuan Khoi
- Hoang, Thi Anh Thu
- Le, Tuan Anh
- Vuong, Dinh Thy Hao
- Nguyen, Dac Nhan Tam
- Dang, Van Khiem
- Nguyen, Thi Oanh
- Pham, Van Luan
- Nguyen, Minh Hai
- Vo, Thi Huyen Trang
- Do, Hung Kien
- Vu, Ha Thanh
- Nguyen, Thi Thuy Hang
- Pham, Van Thai
- Trinh, Le Huy
- Nguyen, Khac Dung
- Nguyen, Hoang Gia
- Truong, Cong Minh
- Pham, Tran Minh Chau
- Nguyen, Thi Bich Phuong
- SpringerLink (Online service)
Ähnliche Objekte (12)
Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer
Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
Synergistic cytotoxicity of the CDK4 inhibitor Fascaplysin in combination with EGFR inhibitor Afatinib against Non-small Cell Lung Cancer
Real-world study of afatinib in first-line or re-challenge settings for patients with EGFR mutant non-small cell lung cancer
Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study
Correction to: The Difference in Clinical Outcomes Between Osimertinib and Afatinib for First-Line Treatment in Patients with Advanced and Recurrent EGFR-Mutant Non-Small Cell Lung Cancer in Taiwan
Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer
Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence
The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer